ClinicalTrials.gg
RecruitingNCT07342049ConvaVAC VLUUpdated Jul 9, 2026

ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds

An interventional study of ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Venous Leg Ulcer (VLU), sponsored by ConvaTec Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by ConvaTec Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Varicose Ulcer with a site in United Kingdom — 3 open to participants now, 6 under way, 1 of them phase 3. Varicose Ulcer · United Kingdom.

Planned enrollment
15th of 32
87 · median 80
Started
2026
the only one that year
No phase
25 of 38
2 open now
Registered
38th of 38
by date
Lead sponsor
2 of 38
ConvaTec Inc.

Among the 38 studies in Varicose Ulcer with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2026, is one of 25 with no phase, and was the 38th registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

3 of the 38 studies in Varicose Ulcer with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Varicose Ulcer with a site in United Kingdom, or all of them as a file.
02

Study summary

Purpose of this study is to learn more about how safe and effective the ConvaVAC™ Ag+ wound therapy system is in treating certain types of long-lasting wounds, called chronic wounds. In this study, the focus is on Venous Leg Ulcers (VLUs). Chronic wounds are wounds that do not heal properly or take a long time to heal. They can cause pain, discomfort, and affect your day-to-day life. These types of wounds are also challenging for healthcare teams to treat and can take up a lot of healthcare resources. Venous Leg Ulcers (VLUs) are the most common type of chronic leg wound and affect about 1 in every 100 people. Usual treatments for VLUs include cleaning the wound, using special dressings, applying pressure (compression therapy), and sometimes using creams or dressings that contain silver to fight infection. This study is being done to see if the wound therapy system can help heal venous leg ulcers more effectively and safely.

Read the detailed description

Chronic wounds, also sometimes referred to as hard-to-heal wounds, are defined as wounds that do not transition through the normal phases of healing in a timely manner. These wounds reduce health-related quality-of-life (QoL) for the patient and pose a substantial burden on healthcare professionals (HCPs) and healthcare systems. The number of chronic wounds is rising. With a global prevalence of \~1.9 per 1,000 and 1-2% in developed countries, it is predicted that the incidence of chronic wounds will increase with the aging population. Wound care accounts for 2-4% of healthcare expenditure in Europe and costs $28 billion per year in the United States.

A significant contributing factor to the delayed healing of chronic wounds is the increased risk of infection. Evidence suggests that biofilm comprises at least 78% of chronic wounds. Biofilm is communities of microorganisms embedded in a matrix of extracellular polymeric substances. This matrix protects microorganisms from antibiotics, antiseptics and the host immune response. The development of biofilm in wounds elicits a sub-optimal host inflammatory response, and is a precursor of local infection. The presence of biofilm-forming microorganisms leads to a four-fold higher chance of infection in chronic wounds compared with non-biofilm forming microorganisms (p=0.0001). The presence of biofilm in wounds can also lead to the failure of antibiotics.

Silver ions kill micro-organisms rapidly by blocking enzyme activity associated with respiration, impairing DNA synthesis and affecting cell structure. Silver is also thought to reduce bacterial adhesion and destabilize biofilm as well as increase susceptibility of bacteria to antibiotics. In recent years, a wide range of wound dressings containing elemental silver or silver releasing compounds have been developed and have gained considerable popularity. Silver dressings reduce wound healing times, hospital stays, dressing change frequency, the requirement for analgesia and reduce the number of MRSA-infected wounds. Several systematic literature reviews have been conducted highlighting the positive effects of using silver dressings on chronic wounds One of the most prevalent chronic wounds is venous leg ulcers (VLUs). Chronic leg ulcers affect around 1% (increasing to 4% in elderly populations) of the population, VLUs account for up to 90% of all chronic leg ulcers. Standard treatment of VLUs includes local wound management (e.g. debridement, moist dressings), compression therapy and topical antimicrobials. Despite standard treatment, VLUs are often associated with pain, reduced mobility, an increased risk of infection and extensive healing times. Such effects ultimately contribute to a reduced patient QoL. Only about half of VLUs heal within 4 months and recurrence rate is as high as 57% within the first year. This leaves a significant proportion of non-healing ulcers which place a burden on heath resources and patient QoL. Improvements in healing of VLUs would have a significant impact.

A promising preventative intervention is Negative Pressure Wound Therapy (NPWT), first described in the 1990's NPWT was originally designed for the treatment of open wounds. NPWT consists of a closed sealed system, the wound is covered with a foam or gauze dressing and sealed with an occlusive film. Intermittent or continuous sub-atmospheric pressure is created by a vacuum pump which draws excess fluid from the wound and collects it in a connected waste liquid collector. The system promotes granulation tissue formation, increases tissue blood flow, increases lymphatic clearance and removes bacteria from the wound bed. It therefore has the potential to improve wound outcomes rather than just manage the symptoms. NPWT has been found to be an effective treatment to heal chronic, complex and infected wounds. Recently, NPWT has been recommended in the management of chronic wounds including VLUs.

03

Conditions studied

  • Venous Leg Ulcer (VLU)

Browse trials for

Keywords

  • Venous Leg Ulcer
  • Negative Pressure Wound Therapy
  • Silver ions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A wound which is amenable to NPWT and is a VLU as defined by CEAP Classification of C6 or C6R
  • Wounds that are clean or contaminated
  • Wounds with at least one sign or symptom of infection
  • Wounds that in the opinion of the investigator would benefit from an antimicrobial dressing
  • ≥18 years old at the time of consent

Exclusion criteria

Exclusion Criteria:

  • Known sensitivities or allergies to components of the ConvaVAC™ Ag+ NPWT System
  • Ischemic wounds with necrotic tissue or eschar present that require sharp debridement
  • Wound is too small or too large based on wound dressing size (> 0.5cm2 and \< 100cm2)
  • Wound depth >7cm
  • Wounds requiring concomitant use of DuoDERM® gel, hydrogels, petroleum-based creams/ ointment-/gels per the opinion of the investigator
  • Active chemotherapy, radiation therapy, or immunotherapy for cancer or completed treatment within the last 3 months
  • Any active at site of dressing application
  • Exposed bone in target wound
  • Exposed blood vessels or nerves in target wound
  • Systemic infection and/or systemic inflammatory response syndrome (SIRS), sepsis
  • Cellulitis in target wound
  • Untreated deep tissue infection including but not limited to osteomyelitis, septic arthritis
  • Active Pregnancy
  • Subjects that in the opinion of the investigator are not suitable for enrollment
  • Vulnerable subjects as determined by ICH Harmonized Guideline, Good Clinical Practice E6(R2)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    ConvaVAC Ag+

    Negative Pressure Wound Therapy system

    Device: ConvaVAC™ Ag+ Negative Pressure Wound Therapy System

Interventions

  • DeviceConvaVAC™ Ag+ Negative Pressure Wound Therapy System

    ConvaVAC™ Ag+ Negative Pressure Wound Therapy System

06

What researchers measure

Primary outcomes

  1. Percentage area reduction (PAR) in wound size at day 14

    Difference between wound area at day 0 and day 14 of treatment

    Time frame: 14 days

07

Study locations

7 of 7 sites recruiting
  • ConvaCare Clinic
    Santiago, Santiago Metropolitan, Chile
    Recruiting
    • Jeison D Peñuela · Contactjeisondavidpa@gmail.com · +56934249429
    • Jocelyn Rojas · Contact
    • Jeison Peñuela · Principal investigator
    • Belen Vallejos · Sub investigator
  • Middlewood Partnership
    Bollington, Cheshire SK10 5JH, United Kingdom
    Recruiting
  • Knutsford Medical Partnership
    Knutsford, Cheshire WA16 9DX, United Kingdom
    Recruiting
    • Thomas Morgan · Contactthomas.morgan@nhs.net · 01565 743100
    • Helen Hodgson · Contacth.hodgson1@nhs.net · 01565 743100
    • Thomas Morgan, Dr · Principal investigator
    • Sean Morris, Dr · Sub investigator
  • Dorset County Hospital NHS Foundation Trust
    Dorchester, Dorset DT1 2JY, United Kingdom
    Recruiting
  • Assured Clinical Research Ltd
    Swaffham, Norfolk PE37 7RD, United Kingdom
    Recruiting
  • Northumbria Healthcare NHS Foundation Trust
    Ashington, Northumberland NE630HP, United Kingdom
    Recruiting
  • Nottingham University Hospitals NHS Trust
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
    Recruiting
    • Christopher Cruse · Contactchristopher.cruse@nhs.net · 0115 924 9924
    • David A Sidloff, Dr · Principal investigator
    • Margherita Dambrini · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

Of 67 industry-sponsored interventional studies with no phase under Varicose Ulcer, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 9 months is below that.

Counting every sponsor, half of 134 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 15, 2026
StartActual
Jan 12, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07342049
Lead sponsor
ConvaTec Inc.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Jan 12, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Jul 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion